Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by FredTheVoiceon Mar 19, 2018 7:49am
151 Views
Post# 27737922

RE:Article in Montreal newspaper La Presse

RE:Article in Montreal newspaper La PresseVery good OLDACE. Thanks for sharing.
Its a good interview.
LUC TANGUAY finishes talking about the new drugs hes lookin for to give some work to TH in the US: "En entrevue, il prfre parler de son entreprise. De ses projets. Il est la recherche de nouveaux mdicaments pour son quipe de vente aux tats-Unis. Quelque 65 personnes, contre 30 Montral. « a serait idal que d'ici 12 18 mois, on ait trois ou quatre produits vendre, dit-il. J'aimerais bien que mes quipes aient a pour travailler.".

AND: its clear that approbation in Canada is not a priority: not happy with the energy lost regarding the first drug (EGRIFTA) not reimboursed by QUEBEC and other provinves. For him its clear, they are other ways more simple for poeple to get TROGARZO if they need it.

Good article. 12 months..........TH will surprise us this year...........it will be a BIG YEAR for the company.

FTV.
Bullboard Posts